AstraZeneca makes $15B bet on China to expand manufacturing and R&D
AstraZeneca, already one of the leading pharmaceutical companies in China, is extending its reach in the country that's become a go-to place for drug R&D and industry dealmaking in the past year....
View ArticleAgomab anticipates $182M IPO as it builds fibrosis pipeline
Belgian fibrosis biotech Agomab Therapeutics plans to collect about $182 million in net proceeds from its proposed Nasdaq IPO. The company anticipates selling 12.5 million shares at $15 to $17 each...
View ArticleSummit gets November PDUFA date for its PD-1xVEGF bispecific
The leader in the next frontier of immuno-oncology officially has a date with the FDA. Summit Therapeutics announced Thursday morning that US regulators have accepted its submission package for the...
View ArticlePipeline cuts for Sanofi; Breakthru Medicine raises $60M
✂️ Sanofi culls several programs: The move comes as part of its “regular portfolio reviews,” a spokesperson said in an email. One candidate affected was amlitelimab, which is no longer in mid-stage...
View ArticleThe disrupted fate of pharmacy startups
Last week, the House Judiciary Committee came out with a report about CVS Health’s alleged antitrust behavior toward disruptive pharmacy models that provide digital services to other pharmacies. It...
View ArticleSanofi vows to stay committed to vaccines as portfolio takes a hit
Sanofi CEO Paul Hudson emphasized the company’s commitment to vaccine development in the face of an increasingly challenging sales environment and its decision to abandon an mRNA-based flu vaccine...
View ArticleWhite House postpones planned TrumpRx launch event
The White House is punting the launch of TrumpRx, the administration’s hub for direct-to-consumer websites run by large drugmakers. The event was expected to take place Friday, but it’s been postponed,...
View ArticleTakeda is ‘not in favor’ of Trump’s MFN deals, CEO-designate says
Takeda’s incoming CEO took a firm stance against President Donald Trump’s “most favored nation” deals with drugmakers on Thursday, while Sanofi and Roche shared new details about their negotiations...
View ArticleTakeda 'anticipated' Medicare negotiations for top seller Entyvio
Incoming Takeda CEO Julie Kim says the drugmaker "anticipated" this week's selection of Entyvio for Medicare negotiations. But for now, the company isn't ready to comment on how the process could...
View ArticleAstraZeneca pays $1.2B for CSPC's long-acting obesity drugs
AstraZeneca is already delivering on its $15 billion commitment to China with a $1.2 billion upfront pact with CSPC Pharmaceutical, spanning eight drug programs and multiple platform technologies. On...
View ArticleReed Jobs' cancer biotech investment firm Yosemite eyes $350M fund
Yosemite, the cancer research investment firm led by Reed Jobs, is looking to raise a fund worth up to $350 million, according to a Thursday SEC filing. The California-based investment firm ...
View ArticleJanux hires CMO after T cell engager deal with Bristol Myers; A batch of...
→ William Go has replaced Zachariah McIver as CMO of Janux Therapeutics, a San Diego-based biotech that is partnering with Bristol Myers Squibb on a T cell engager ...
View ArticleLilly unveils $3.5B factory that will make retatrutide and other obesity drugs
Eli Lilly has budgeted $3.5 billion for a new weight loss injectable and device factory in Lehigh Valley, PA, which will manufacture its next-gen obesity drug retatrutide. The factory will also produce...
View ArticleAmgen ends partnership with Kyowa Kirin on immunology drug, despite Phase 3 wins
Amgen abruptly pulled out of a collaboration for a leading drug in its immunology pipeline on Friday, sending the asset back to its partner ahead of an FDA submission later this year. Amgen terminated...
View ArticleModerna licenses Phase 3 asset to Recordati; ProMIS' private placement
Plus, news about Lexicon Pharmaceuticals, Vaxcyte, ALX Oncology, BioMarin and 2048 Ventures: 🤝 Moderna signs rare disease drug deal with Recordati: The Italian drugmaker will pay Moderna $50 million...
View ArticleQuince's steroid therapy for rare disease fails, shares tank
Quince Therapeutics' once-monthly steroid-based treatment failed a Phase 3 trial for a rare genetic condition called ataxia-telangiectasia, prompting the Bay Area company to say it would stop...
View ArticleUltragenyx resubmits gene therapy for rare neuro disease to FDA
Ultragenyx has resubmitted its approval request for a rare disease gene therapy after the FDA rejected it last summer. UX111 is an AAV gene therapy designed to treat Sanfilippo syndrome type A. The...
View ArticleCHMP opposes Lilly’s Mounjaro in heart failure, backs Novo’s Kayshild
EU regulators have refused to greenlight Eli Lilly’s weight loss drug Mounjaro as a treatment for a type of heart failure, while giving the go-ahead for Novo Nordisk’s semaglutide in liver disease....
View ArticleBitterroot reverts to preclinical biotech in CD47 as CEO leaves
Bitterroot Bio, a biotech from leading minds in the CD47 field, appears to have returned to the discovery stage after attempting to expand the potential of the "don't eat me" signal from the cancer...
View Article